Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

18.81
+0.53002.90%
Volume:511.13K
Turnover:9.36M
Market Cap:867.60M
PE:85.50
High:18.90
Open:17.92
Low:17.67
Close:18.28
52wk High:64.23
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:0.33
T/O Rate:1.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2200
EPS(LYR):1.80
ROE:5.10%
ROA:-0.48%
PB:3.57
PE(LYR):10.45

Loading ...

A Look At Oddity Tech (ODD) Valuation After Class Action Lawsuit On Advertising Disclosures

Simply Wall St.
·
May 01

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

GlobeNewswire
·
Apr 30

Oddity price target lowered to $14 from $18 at Jefferies

TIPRANKS
·
Apr 29

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report

prnewswire
·
Apr 28

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27

Oddity Tech faces shareholder class action over alleged advertising cost disclosure omissions

Reuters
·
Apr 23

Radiopharm Theranostics Reports Business Update

GlobeNewswire
·
Apr 23

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

GlobeNewswire
·
Apr 21

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

TIPRANKS
·
Apr 17

ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The West Australian
·
Apr 17

Oddity Tech faces securities class action over alleged misleading ad efficiency disclosures

Reuters
·
Apr 16

A Look At Oddity Tech (ODD) Valuation As Securities Class Action Raises Questions On Customer Acquisition Costs

Simply Wall St.
·
Apr 11

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire
·
Apr 09

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

GlobeNewswire
·
Apr 09

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

GlobeNewswire
·
Apr 08

Kodiak AI Expands Autonomous Trucking Beyond the Sunbelt with Demonstrations in Ohio and Indiana

GlobeNewswire
·
Apr 08

Oddity Tech (ODD) Faces Investor Lawsuit Over Alleged Ad Algorithm Disclosures

TIPRANKS
·
Apr 08

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

GlobeNewswire
·
Mar 30

Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 30

ODDITY Tech Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Mar 28